{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:42:35Z","timestamp":1787020955112,"version":"build-2736575974"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cefazolin is a first-generation cephalosporin commonly used for skin and soft tissue infections, abdominal and orthopedic surgery prophylaxis, and methicillin-sensitive staph aureus. Cephalosporins as a whole are known potential inducers of hemolytic anemia; however, mechanism of action is primarily autoimmune, and compared to other drugs, cefazolin is the least common.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A rare case report of cefazolin-induced hemolytic anemia \u201cCIHA\u201d and a systematic review of CIHA articles in English literature. Two authors performed review of publications and articles were selected based on inclusion and exclusion criteria. A systematic search of the literature yielded 768 entries with five case reports on cefazolin-induced hemolytic anemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation\/results<\/jats:title>\n                    <jats:p>An 80-year-old female with methicillin-sensitive Staphylococcus aureus \u201cMSSA\u201d endocarditis. The patient was started on intravenous \u201cIV\u201d cefazolin that that resulted in hemolytic anemia and eosinophilia. Switching to vancomycin improved hemoglobin level and resolved eosinophilia. Four cefazolin-induced hemolytic anemia case reports and one population-based article with a case reported were analyzed with respect to direct antiglobulin test \u201cDAT\u201d (also known as the direct Coombs test) results, prior penicillin sensitivity, and acute anemia causes exclusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CIHA is a rare cause of clinically significant anemia. The diagnosis of drug-induced anemia is one of exclusion. It is important to consider DAT results and prior penicillin sensitivity when evaluating a patient for cefazolin-induced hemolytic anemia. However, the frequency of cefazolin use and resultant anemia necessitates early recognition of hemolytic anemia and prompt discontinuation of cefazolin, especially with long-term use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40001-021-00604-9","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T07:03:17Z","timestamp":1637737397000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cefazolin-induced hemolytic anemia: a case report and systematic review of literature"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4405-9210","authenticated-orcid":false,"given":"Elizabeth","family":"Mause","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Selim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manasa","family":"Velagapudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,24]]},"reference":[{"issue":"1","key":"604_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1182\/asheducation-2009.1.73","volume":"2009","author":"G Garratty","year":"2009","unstructured":"Garratty G. Drug-induced immune hemolytic anemia. Hematology. 2009;2009(1):73\u20139. https:\/\/doi.org\/10.1182\/asheducation-2009.1.73.","journal-title":"Hematology"},{"issue":"3","key":"604_CR2","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1046\/j.1537-2995.1978.18378205151.x","volume":"18","author":"JL Moake","year":"1978","unstructured":"Moake JL. Hemolysis induced by cefazolin and cephalothin in a patient with penicillin sensitivity. Transfusion. 1978;18(3):369.","journal-title":"Transfusion"},{"issue":"8","key":"604_CR3","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.jamda.2008.05.001","volume":"9","author":"SN Imam","year":"2008","unstructured":"Imam SN, Wright K, Bhoopalam N, Choudhury A. Hemolytic anemia from ceftriaxone in an elderly patient: a case report. J Am Med Dir Assoc. 2008;9(8):610\u20131. https:\/\/doi.org\/10.1016\/j.jamda.2008.05.001.","journal-title":"J Am Med Dir Assoc"},{"key":"604_CR4","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/BLO.0b013e31803d3aad","volume":"459","author":"DL Cerynik","year":"2007","unstructured":"Cerynik DL, Lee G, Fayssoux R, Amin NH. Case report: cefazolin-induced hemolytic anemia. Clin Orthop Relat Res. 2007;459:260\u20132. https:\/\/doi.org\/10.1097\/BLO.0b013e31803d3aad.","journal-title":"Clin Orthop Relat Res"},{"issue":"3","key":"604_CR5","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jaci.2014.07.062","volume":"135","author":"E Macy","year":"2014","unstructured":"Macy E, Contreras R. Adverse reactions associated with oral and parenteral use of cephalosporins: a retrospective population-based analysis. J Allergy Clin Immunol. 2014;135(3):745\u201352. https:\/\/doi.org\/10.1016\/j.jaci.2014.07.062.","journal-title":"J Allergy Clin Immunol"},{"key":"604_CR6","doi-asserted-by":"publisher","DOI":"10.4172\/2161-0681.1000296","author":"M Moghaddam","year":"2016","unstructured":"Moghaddam M, Razzaghi F, Sheibani H, Pourfathollah AA. A fatal case of cefazolin-induced immune hemolytic anemia in Iran. J Clin Exp Pathol. 2016. https:\/\/doi.org\/10.4172\/2161-0681.1000296.","journal-title":"J Clin Exp Pathol"},{"issue":"4","key":"604_CR7","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/j.1537-2995.2007.01173.x","volume":"47","author":"ST Johnson","year":"2007","unstructured":"Johnson ST, Fueger JT, Gottschall JL. One center\u2019s experience: the serology and drugs associated with drug-induced immune hemolytic anemia\u2014a new paradigm. Transfusion. 2007;47(4):697\u2013702. https:\/\/doi.org\/10.1111\/j.1537-2995.2007.01173.x.","journal-title":"Transfusion"},{"issue":"3","key":"604_CR8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.transci.2009.03.017","volume":"40","author":"ST Johnson","year":"2009","unstructured":"Johnson ST. Drug-induced immune hemolytic anemia. Transfus Apheres Sci. 2009;40(3):205\u20137. https:\/\/doi.org\/10.1016\/j.transci.2009.03.017.","journal-title":"Transfus Apheres Sci"},{"issue":"12","key":"604_CR9","doi-asserted-by":"publisher","first-page":"575","DOI":"10.7164\/antibiotics.23.575","volume":"23","author":"Y Mine","year":"1970","unstructured":"Mine Y, Nishida M, Goto S, Kuwahara S. Studies on direct coombs reaction by cefazolin in vitro. J Antibiot. 1970;23(12):575\u201380. https:\/\/doi.org\/10.7164\/antibiotics.23.575.","journal-title":"J Antibiot"},{"key":"604_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40629-019-0100-8","volume":"28","author":"G Wurpts","year":"2019","unstructured":"Wurpts G, Aberer W, Dickel H, et al. Guideline on diagnostic procedures for suspected hypersensitivity to beta-lactam antibiotics. Allergo J Int. 2019;28:121\u201351. https:\/\/doi.org\/10.1007\/s40629-019-0100-8.","journal-title":"Allergo J Int"},{"issue":"2","key":"604_CR11","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jama.2018.19283","volume":"321","author":"ES Shenoy","year":"2019","unstructured":"Shenoy ES, Macy E, Rowe T, Blumenthal KG. Evaluation and management of penicillin allergy: a review. JAMA. 2019;321(2):188\u201399. https:\/\/doi.org\/10.1001\/jama.2018.19283.","journal-title":"JAMA"},{"issue":"11","key":"604_CR12","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1111\/j.1365-2222.2011.03846.x","volume":"41","author":"A Pipet","year":"2011","unstructured":"Pipet A, Veyrac G, Wessel F, et al. A statement on cefazolin immediate hypersensitivity: data from a large database, and focus on the cross-reactivities. Clin Exp Allergy. 2011;41(11):1602\u20138. https:\/\/doi.org\/10.1111\/j.1365-2222.2011.03846.x.","journal-title":"Clin Exp Allergy"},{"issue":"4\u20135","key":"604_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.blre.2010.06.004","volume":"24","author":"G Garraty","year":"2010","unstructured":"Garraty G. Immune hemolytic anemia associated with drug therapy. Blood Rev. 2010;24(4\u20135):143\u201350. https:\/\/doi.org\/10.1016\/j.blre.2010.06.004.","journal-title":"Blood Rev"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-021-00604-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-021-00604-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-021-00604-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T07:29:02Z","timestamp":1637738942000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-021-00604-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,24]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["604"],"URL":"https:\/\/doi.org\/10.1186\/s40001-021-00604-9","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,24]]},"assertion":[{"value":"25 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient has consented to the submission of the case report to the journal. Informed consent was obtained from the patient for publication. A copy of the written consent is available for review by the Editors-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}